𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination Therapy of Imatinib Mesylate and Interferon-α Demonstrates Minimal Activity and Significant Toxicity in Metastatic Renal Cell Carcinoma: Results of a Single-Institution Phase II Trial

✍ Scribed by Blase N. Polite; Apurva A. Desai; Beth Manchen; Walter M. Stadler

Book ID
115075912
Publisher
CIG Media Group, LP.
Year
2006
Tongue
English
Weight
502 KB
Volume
4
Category
Article
ISSN
1558-7673

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Subcutaneous interleukin-2 and interfero
Subcutaneous interleukin-2 and interferon α in the treatment of patients with metastatic renal cell carcinoma—Less efficacy compared with intravenous interleukin-2 and interferon α : Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie
✍ Alain Ravaud; Rémy Delva; Fréderic Gomez; Christine Chevreau; Jean-Yves Douillar 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## Background: The main objective of this trial was to evaluate the combination of subcutaneous (sc) interleukin-2 (il-2) with interferon alpha-2a (ifn-alpha) in the treatment of patients with metastatic renal cell carcinoma (mrcc) compared with a previous trial that used continuous-infusion il-2 a